Get access to our best features
Get Started
Subscribe
Israel-Hamas Conflict
Joe Biden
US Economy
Donald Trump
US Politics
Independence Day
Democratic Party
Parade
Kamala Harris
Heatwaves
US Social Issues
White House
US Crime
Get access to our best features
Get Started
Published 10 days ago

Zealand Offers $900 Million in Shares to Fund New Obesity Drugs

Summary by Bloomberg
Zealand Pharma A/S is selling about 6.3 billion Danish kroner ($900 million) in new shares to fund development of its experimental obesity drugs, as the Danish biotech challenges Novo Nordisk A/S in the growing market.

0 Articles

All
Left
Center
Right
BloombergBloomberg

Zealand Offers $900 Million in Shares to Fund New Obesity Drugs

Zealand Pharma A/S is selling about 6.3 billion Danish kroner ($900 million) in new shares to fund development of its experimental obesity drugs, as the Danish biotech challenges Novo Nordisk A/S in the growing market.

10 days ago·United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe
Ground News Article Assistant
Not enough coverage to generate an Article Assistant.

Bias Distribution

  • 100% of the sources lean Left
100% Left
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Novo NordiskNovo Nordisk
DenmarkDenmark
Trending Topics
Ground News logo
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble NewsletterTimelines
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2024 Snapwise Inc.
News
For You
Search
BlindspotLocal